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Abstract
The question why patients with controlled glaucoma continue to lose their vision and 
may end with blindness was raised at the conference last year, but no answer was pro-
vided. This presentation will address some of the possible clinical causes such as supine 
position during sleep and sleeping on the affected eye(s). Antihypertensive drugs at 
bedtime increase the risk of anterior ischemic optic neuropathy, which is a challenge 
to diagnose in advanced glaucoma. Basic causes include the continuation of neuronal 
apoptosis despite controlled intraocular pressure. To prevent further visual loss in these 
patients, practical steps such as sleeping at 20–30° head-up position, avoiding sleeping on 
the affected eye(s), avoiding taking antihypertensive drugs at bedtime, and developing 
antiapoptotic drugs such as antibodies are essential.
Keywords: glaucoma, visual field damage, scotoma, blindness, prevention, intraocular 
pressure, supine position, antihypertensive drugs, apoptosis
1. Introduction
Glaucoma is a group of diseases that affect the optic disc, causing a specific type of optic 
neuropathy characterized by specific changes in the optic disc and visual field that eventually 
may progress to blindness. A feature common to most of the glaucoma types is high intraocu-
lar pressure, which to date is virtually the only target for treatment. The aim of the treatment 
is to decrease the intraocular pressure to a target pressure that is specific for each patient. 
This specific pressure is supposed to prevent further deterioration in visual field and irrevers-
ible blindness. Unfortunately, despite achieving a target pressure, there is a subpopulation of 
glaucoma patients who still progress gradually to blindness. This chapter will discuss pos-
sible reasons for this phenomenon in those patients who achieve the target pressure.
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2. Epidemiology of blindness
The World Health Organization (WHO) estimated that in 2014, 285 million people (4%) out of 
the 7.2 billion world population had either low vision (246 million) or blindness (49 million) 
[1]. Ninety percent of these live in low-economic settings and 82% are aged over 50 years. 
Eighty percent of visual impairment can be prevented or cured. The best examples are correc-
tion of refractive errors and cataract surgery.
The most common cause for blindness worldwide is cataract (47%), and it is reversible upon 
surgery. The second common cause for blindness is glaucoma (12%), and it is the most 
common cause for irreversible blindness. This is followed by age-related macular degenera- 
tion (5%).
3. Blindness from glaucoma
Glaucoma is a distinctive group of optic nerve neuropathies characterized by specific optic 
disc and visual field changes, usually with an increase in intraocular pressure (IOP). In the 
past, a true IOP of up to 21 mmHg was considered normal in healthy individuals. Today, 
some consider an IOP between 18 and 22 as borderline. The term “true IOP” addresses the 
corrected IOP according to the thickness of the cornea and other parameters that influence the 
IOP. The main optic disc change is the increase of the cup (cupping) and decrease of the rim 
that contains the axons from the retinal ganglion layer (Figure 1). Early signs for this include 
disc notching, increased excavation, retinal nerve fiber defects, and papillary flame-shape 
hemorrhages. The early changes in visual field include Bjerrum defects (scotomata), paracen-
tral scotoma, nasal step, and arcuate scotoma. As the disease progresses, visual field defects 
increase, first in depth and then in size. Arcuate scotoma may join nasal field, and when these 
increase toward the center and the periphery, tunnel vision and/or a temporal crescent or a 
Figure 1. An advanced stage of glaucomatous optic disc damage showing thinning of the rim. The cup/disc ratio is 
almost 1 (subtotal excavation).
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few visual islands remains. Eventually, these disappear too and the patient remains with no 
light perception. The changes in visual field correspond and follow closely with the changes 
in the optic disc. The chronic forms of this group are asymptomatic until advanced and irre-
versible visual loss occurs. Patients preserve normal visual acuity (even of 20/20) in one or 
both eyes until late in the disease. Such patients may not be aware of the small defects early in 
the course of the disease or even advanced concentric visual loss and tunnel vision, until they 
completely lose their vision in one or both eyes.
Two theories explain the neuronal loss in glaucoma. The first claims that mechanical force 
exerted on the optic disc causes direct destruction. The second claims that compromised 
blood flow causes damage. The damage may be caused also by a combination of these two 
processes. The end point is apoptosis of the ganglion cell layer.
4. Pattern of visual loss in glaucoma
The visual field loss (scotoma) in glaucoma has a distinctive pattern that differs from visual 
loss due to other causes (Figures 2 and 3). The visual field defects include Bjerrum scotoma, 
paracentral scotoma, nasal step, and arcuate defect. These defects correspond to retinal nerve 
Figure 2. Advanced visual field loss of the right eye in a glaucoma patient. On the left, a 24-2 Humphrey visual field 
demonstrating a concentric visual field loss with only a small para-central island remained. The fixation point is split. 
This is also demonstrated in the same patient on the right with a 10-2 visual field. Glaucoma surgery at this point can 
cause the loss of the fixation and a decrease in best-corrected visual acuity to counting fingers.
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Figure 3. 24-2 and 10-2 Humphrey visual fields of a patient with advanced field damage. The damage encroaches on the 
fixation but does not split it. In this case, successful trabeculectomy with mitomycin-C was performed. The visual field 
remained unchanged. The best-corrected visual acuity remained 20/60, and the intraocular pressure decreased from 28 
to 34 mmHg to 10–12 mmHg and remained at this level.
fiber loss, which usually begins in the arcuate bundles and the nasal fibers and ends with the 
papillomacular bundle.
When superior and inferior nasal steps coalescence with arcuate defects and spread centrally 
and peripherally, tunnel vision evolves. The visual acuity may remain intact (best-corrected 
visual acuity 20/20) in this situation. Eventually, central vision and/ or temporal peripheral 
island(s) may remain; when these are lost, the patient remains with no light perception. 
Occurrence in both eyes results in total blindness. In most types of glaucoma, the chronic 
ones, the patient may not be aware of the visual field loss, unless comparing each eye to the 
other. This is the reason that glaucoma is called the silent thief of vision. The patient may 
present only when the visual acuity in one eye is completely lost because the overlapping 
between the visual field of both eyes, micro-saccades, and most importantly, turning the head 
toward the area of interest. Therefore, screening of the population is the most crucial measure 
to detect glaucoma patients and treat them early.
The goal of treatment is to stabilize the visual field and prevent further deterioration in visual 
field and visual loss. Unfortunately, currently, the main treatment is aimed only at reducing 
the intraocular pressure (IOP) and achieving the ideal IOP (target IOP), which differs for 
each patient and is determined by the type of glaucoma, its severity, progression, patient 
compliance, and allergy to medications. In general, it should be as low as possible but not too 
low (hypotonia). Screening of the population includes observing the optic disc and checking 
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the IOP. It should be performed at least every 5 years before the age of 40 years and every 
6 months after the age of 40 years.
5. Prevention of visual loss
To date, visual loss in glaucoma is irreversible because of the death of ganglion cells and 
their axons. The treatment is aimed to prevent continuous visual field loss and is divided into 
medical, laser, and surgical methods. To prevent visual field loss, the intraocular pressure 
should be at or below the target IOP, which is individual to each patient and related to the 
type of glaucoma, severity of the disease, patient’s compliance, and allergy to medications. To 
date, there is no treatment addressing the different genetic defects and molecular mechanisms 
causing or related to glaucoma. The first line of treatment is usually medications. To enhance 
treatment, laser treatment may be applied. Some of the laser treatments such as selective laser 
trabeculoplasty have a short span of effectiveness, usually 1–1.5 years. If these fail, surgery 
is indicated. The number of medications, laser, and surgical procedures is wide and is deter-
mined mainly by the type of glaucoma.
Screening for glaucoma should include the entire population and should be composed of 
observation of the optic disc and documentation of the cup-disc ratio (C/D ratio) and other 
features of glaucomatous optic disc damage and intraocular pressure. Screening is usually 
performed every 5 years and over the age of 40 years twice a year. Patients with higher risk for 
glaucoma (e.g., family history of glaucoma, pseudoexfoliative syndrome, pigmentary disper-
sion syndrome, borderline IOP, etc.) may be routinely evaluated more often. Every patient who 
is diagnosed with glaucoma should be on appropriate medications permanently unless suc-
cessful surgery has been performed, and even than the patient should be routinely followed.
The follow-up is every 3–4 months for lifetime including after successful surgery. If aggravation 
occurs, the follow-up intervals may be more frequent. Examination should be performed at dif-
ferent hours of the day, and a diurnal curve is indicated for patients with controlled IOP under 
medications and continuous visual field damage. The diurnal curve is performed every 4 hours 
and may even be increased to every 2 hours under medications. Some types of glaucoma such as 
pseudoexfoliative and pigmentary have a high fluctuation rate that may be missed by routine IOP 
examination. It is imperative to perform surgery in a timely manner, before the glaucoma is too 
advanced and before splitting of the fixation on visual field testing. Patients with complete split-
ting of the fixation are at higher risk to lose their central vision after surgery. Except for glaucoma 
surgery, other procedures may be required and may result in decrease of IOP. Cataract surgery 
in presence of risk factors such as hard nucleus (brown, red or black cataract), pseudoexfoliation, 
phakodonesis, lens subluxation, small pupil, ocular surface disorders such as ocular cicatricial 
pemphigoid, and Fuch’s corneal dystrophy should be performed early. As the number of risk 
factors increases, surgery should be performed earlier. Visual field should also be obtained for 
these patients before surgery, if the glaucoma is advanced (C/D ratio of 0.9 or more).
Patients at high risk to lose their vision are those who do not take their medications regularly 
and/or do not follow-up with their ophthalmologist at regular intervals as indicated above. 
Why Do Patients with Controlled Glaucoma Continue to Lose Their Vision?
http://dx.doi.org/10.5772/intechopen.79764
27
Other major factors for visual loss are late diagnosis that may occur with all types of chronic 
glaucomas and slow decision making. Aggressive glaucoma and poor surgical outcomes may 
contribute to visual loss.
6. How to define controlled glaucoma?
The aim of treatment at present is controlling the IOP to prevent further deterioration in 
visual fields. The loss of visual field is irreversible. The ideal IOP should be low enough to 
prevent visual field loss without compromising the functions of the eye. Each patient has a 
desirable range of IOP—target IOP, which varies between individuals and depends on the 
aggressiveness of the disease. The aggressiveness of the disease is determined by the IOP, its 
fluctuations, the type of glaucoma, and the damage to the optic disc and visual field. In nor-
mal tension glaucoma, the target IOP is usually less than in other types of glaucoma, because 
even with normal pressures, the damage continues to progress. The IOP is constantly chang-
ing. It depends on the hour (diurnal variations) and seasons. Most but not all subjects have the 
highest peak in IOP during the early morning.
To be considered as “controlled glaucoma,” the IOP should be within its target during the 
entire day in a long follow-up with constant use of anti-glaucoma medications or postopera-
tively. The patients should take their medications properly at a preset times and continuously. 
Thus, patients intolerant to anti-glaucoma medications or uncompliant are not considered 
controlled. The IOP may be assessed by diurnal curve every 4 hours, usually between 8 AM 
and 8 PM, because it changes constantly or even every 2 hours.
7. Matters of definition
In this chapter, controlled glaucoma was defined as target IOP under diurnal curve of 4 hours 
in patients, who are dedicated in taking their anti-glaucoma medications or after surgery. It is a 
philosophic question whether patients who continue to lose their vision are controlled. Perhaps 
the definition should be patients who do not show further signs of deterioration. However, since 
the target pressure has been achieved, it is expected that the patients will demonstrate stability 
of their visual functions (i.e., visual fields), and this may not occur in a subset of these patients.
8. Reasons for progressive visual field loss despite controlled glaucoma
8.1. High IOP fluctuations
Secondary glaucomas such as pseudoexfoliative and pigmentary glaucomas have high fluctu-
ations of IOP, which varies depending on the dispersion of pseudoexfoliation material or pig-
ment in the anterior chamber angle. The IOP peaks are unpredictable and variable in time and 
amplitude and may be missed by diurnal curve even if performed every 2 hours. They may 
occur between the IOP measurements and may be missed. To overcome this, frequent IOP 
monitoring including at bedtime and at shorter intervals may reveal such patients. Patients 
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with high and large fluctuations that are on full medical treatment may benefit from early 
glaucoma surgery, either trabeculectomy with mitomycin C or shunt procedure. Still, patients 
without IOP fluctuations may progress to blindness from other reasons as stated below.
8.2. Increased IOP in supine position (at bedtime)
People spend about one third of the day (6–8 hours) sleeping. The resting time may increase 
after retirement. The IOP increases at supine position compared with standing or sitting in 
healthy subjects by 2.47 ± 2.12 mmHg (mean ± standard deviation) (p < 0.001) when measured 
by non-contact tonometer Keeler, Pulsair EasyEye [2]. In another study, the IOP in sitting 
position was found to be 13.5 ± 2.0 mmHg in the right eye and 13.2 ± 2.3 mmHg in the left 
eye in healthy individuals [3]. The IOP increased in supine position to 16.8 ± 2.3 mmHg and 
17.0 ± 2.3 mmHg, respectively (p = 0.001). This may result in deterioration of the optic disc and 
visual fields. Diurnal curve has probably no meaning if the patient is awakened at bedtime, 
and the pressure is measured while sitting.
The intracranial pressure (ICP) may also influence the progression of glaucoma [4, 5]. The ICP 
is directed through the subarachnoid space opposite to the IOP through the lamina cribrosa, 
and the difference between them is the translaminar pressure gradient. Theoretically, if this is 
low, the progression may be slower than if it is high but this may not be true. A high ICP and 
IOP with a low gradient may be sufficient to cause increased optic disc damage because of the 
increased shearing force in the lamina cribrosa and decrease in axonal plasma flow. This may 
initiate or facilitate axonal apoptosis.
8.3. Increased IOP when sleeping on the affected eye(s)
Most ophthalmologists do not live with their glaucoma patients and have no idea about their 
behavior in daily life. The patients may sleep on their affected eye(s), and this causes further 
increase of the IOP in addition to the increase caused by supine position. When the eye leans 
against the bed or pillow or when the entire mass of the head is over all or part of the globe, 
IOP is increased by 33%. Thus, the physician should inquire about the sleeping habits of 
the glaucoma patients. Actually, increase in IOP measurement can be seen in patients who 
squeeze their eyes during evaluation with Goldmann tonometer, as well as with some other 
instruments. It can also be seen if the examiner presses the globe during IOP measurement.
8.4. Antihypertensive drugs at bedtime
Glaucoma patients are usually older and have many associated aging and pathologic conditions, 
including atherosclerosis and systemic hypertension. Other ischemic diseases such as diabetes 
mellitus may also be encountered. Taking antihypertensive drugs before sleeping increases the 
risk for anterior ischemic optic neuropathy (AION) [6]. Antihypertensive medications decrease 
the perfusion into the optic disc, and this may join atherosclerotic changes in the blood vessels. 
AION may be difficult to diagnose in patients with advanced glaucoma. In advanced glaucoma, 
the cup may be large (cup/disc ratio of 0.8 or more), and the rim is thin enough not to distinguish 
pallor of the rim following additional AION. In addition, AION field defects may be superim-
posed on the glaucoma visual field defects. In advanced glaucoma, the visual field scotomata 
may be large enough (e.g., tubular vision) to prevent detection of the additional scotomata 
caused by AION. According to the vascular theory, damage to the optic nerve may be caused 
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Figure 4. The pathways of apoptosis. Interference with any of these steps may prevent the apoptosis cascade.
also from ischemia if the optic disc does not receive enough oxygen even without AION. This 
damage is added to the damage caused by the mechanical effect of optic disc compression.
8.5. Continuation of the neuronal apoptosis
Patients with glaucoma suffer loss of axons of the ganglion cells as they pass the optic disc. 
Two theories explain the axonal loss. The first one is mechanical. According to this theory, the 
force caused by the IOP impedes axonal transport (flow) (micro-strangulation) and this may 
trigger axonal apoptosis [7]. The second theory is vascular. This means that the IOP impedes 
vascular supply to the optic disc. This causes a relative ischemia to the optic disc and triggers 
apoptosis. It is probable that both mechanisms coexist and the mechanical force may have a 
greater influence. Nonetheless, apoptosis, and not degeneration/necrosis, is the mechanism of 
axonal death in glaucoma. Apoptosis is programmed cell death, while necrosis is a different 
process involving extracellular components of inflammation. It consists of several pathways 
initiated be certain extracellular ligands such as programmed death ligand 1 (PD-L1), Fas 
ligand (FasL), tumor necrosis factor (TNF), nerve growth factor (NGF), growth factors, and 
others (Figure 4) [8, 9]. These molecules attach to receptors on the cell wall such as tropo-
myosin kinase receptor (TRK), tyrosine kinase receptor (RTK), receptor of apoptosis signal 
factor (Fas), and tissue necrosis factor receptor (TNFR) that trigger intracellular cascades that 
involve multiple pathways and molecules including the caspase cascade. These processes 
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occur in the cytoplasm, endoplasmic reticulum, and mitochondria that lead signals to the 
nucleus to degenerate. The end result is shrinkage of the nucleus, fragmentation of the deoxy-
ribonucleic acid (DNA), and death of the cell. It is possible that some additional mechanisms 
and pathways exist that involve adjacent cells such as astrocytes, oligodendrocytes, and even 
vascular endothelial cells. Despite controlled IOP, the apoptosis may continue once started 
causing additional ganglion cell death. Ganglion cells in different stages of apoptosis may 
“signal” adjacent normal cells to commence with apoptosis cascade, leading to further loss 
of neuronal cells.
9. Recommendations to prevent further visual loss in patients with 
controlled glaucoma
Patients with high IOP fluctuations are not controlled and may benefit from early surgery 
such as trabeculectomy with mitomycin C or shunt procedures. These patients can be traced 
because they usually have secondary glaucoma mainly pseudoexfoliative and pigmentary. It 
is worthwhile to ask the patients to sleep at 20–30° head-up position. The IOP decreases when 
the bed head is tilted up in 30° and is 14.2 ± 2.3 mmHg OD and 14.1 ± 1.9 OS and not when the 
patient is sleeping on multiple pillows (16.3 ± 2.4 OD and 16.5 ± 2.6 OS) [3]. In another study, 
the IOP decreased from 16.02 ± 1.65 to 14.5 ± 1.36 mmHg [10]. The IOP may decrease by 9.33% 
in glaucoma patients, and this effect is found in 82% of them. Patients should avoid sleeping 
on their affected eye(s). Sleeping over the back or even on the side as long as the orbital rim 
is lying against the pillow is the best option for these patients. Antihypertensive medications 
should be taken when the patient is awake and active, usually in the morning and not at 
bedtime. It is the physician role to make these recommendations.
Additional efforts should be made to discover drugs that can abolish or slow down the 
apoptosis. Antibodies against PD-L1, FasL, growth factors, or their receptors may be helpful. 
Forty chemical compounds have inhibitory effects on different steps of apoptosis but may 
be toxic to normal cells. Phenoxodiol, an isoflavone that targets a regulator of sphingosine 
kinase depriving the cell of XIAP and FLIP was evaluated for ovarian cancer but was disap-
pointing. Thus, it is essential to discover biologic agents such as antibodies against one or 
more of the extracellular mediators with better effects and with few or no side effects that 
will be approved for clinical use to arrest axonal apoptosis at the optic nerve. So far, none has 
been discovered, and research efforts are mandatory because such molecules may be used in 
glaucoma as well as other fields to prevent cellular few or no by apoptosis.
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